Ya read his old posts, "buyout incoming" on tons of different biotech boards. Arry will be bought out when and if novartis or astra find there ph3 trials effective and think they will be able to get a drug approved. As burnaka has said many times this will be cheaper for them than to not buyout arry
tippytappy, andswhisper throws something out every couple of months. He never has any supporting evidence for his prediction nor does he ever come back and correct himself when he's wrong. Usually when he posts his buddies piehole and others try to bolster his predictions with no more information than you see in this thread. After all this time I wonder if this person is even long the stock. Bottom line, don't hold your breath for any more information and I think by March 31st there will be some other "partnership", "buy out" kind of rumor from yours truly.
Dr. Zabriskie has served as a member of our Board of Directors since January 2001. Dr. Zabriskie is Co-Founder and Director of Puretech Ventures, LLC, and the past Chairman of the Board, Chief Executive Officer and President of NEN Life Science Products, Inc., a leading supplier of kits for labeling and detection of DNA. Prior to joining NEN Life Science Products, Dr. Zabriskie was President and Chief Executive Officer of Pharmacia and Upjohn Inc. As Chairman of the Board and Chief Executive Officer of Upjohn, Dr. Zabriskie led the Upjohn project, which resulted in the $12 billion merger of equals with Pharmacia. Prior to joining Upjohn in 1994, Dr. Zabriskie was Executive Vice President for Merck & Co., Inc. Dr. Zabriskie currently serves on the Board of Directors of publicly-traded Kellogg Co. and ARCA biopharma Inc., and privately-held Puretech Ventures. Dr. Zabriskie received his undergraduate degree in chemistry from Dartmouth College and his Ph.D. in organic chemistry from the University of Rochester.